Abbott nabs CMS reimbursement for FreeStyle Libre continuous glucose monitor


Abbott logoAbbott (NYSE:ABT) said today that its FreeStyle Libre continuous glucose monitor is now available to Medicare patients, after the Centers for Medicare & Medicaid Services determined that the device can be classified as a therapeutic CGM.

The FreeStyle Libre is designed to read glucose levels through a sensor worn on the back of a person’s upper arm for up to 10 days. Abbott touted that its device is the only CGM covered by Medicare that doesn’t require user calibration.

Get the full story at our sister site, Drug Delivery Business News.


DeviceTalks Boston 2018 is Bigger and Better than ever!

textadimage Join us Oct. 8-10 for the 7th annual DeviceTalks Boston, back in the city where it all began.

DeviceTalks offers three days of world-class education, networking, and a technology exhibition featuring the leading companies in the industry.

Early Registration is now open.

Speak Your Mind